These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 11957811)

  • 21. Tumor markers in staging and prognosis of colorectal carcinoma.
    Levy M; Visokai V; Lipska L; Topolcan O
    Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
    Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
    Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer.
    Yakabe T; Nakafusa Y; Sumi K; Miyoshi A; Kitajima Y; Sato S; Noshiro H; Miyazaki K
    Ann Surg Oncol; 2010 Sep; 17(9):2349-56. PubMed ID: 20217258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
    Chen C; Chen LQ; Yang GL; Li Y
    Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19-9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study.
    Yüceyar S; Ertürk S; Dirican A; Cengiz A; Saner H
    Int Surg; 1996; 81(2):136-9. PubMed ID: 8912078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
    Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
    Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
    Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gastrointestinal cancer].
    Takahashi Y
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carcinoembryonic antigen and CA19-9: implications of quantitative marker measurement in tissues for prognosis of colorectal cancer.
    Gebauer G; Müller-Ruchholtz W
    Cancer Detect Prev; 2001; 25(4):344-51. PubMed ID: 11531011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
    Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
    Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid genetic diagnosis with transcription-reverse transcription concerted reaction system for peritoneal recurrence and survival in colorectal cancer patients.
    Hayama T; Iinuma H; Watanabe T
    Oncol Rep; 2007 Oct; 18(4):779-84. PubMed ID: 17786336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix.
    Carmignani CP; Hampton R; Sugarbaker CE; Chang D; Sugarbaker PH
    J Surg Oncol; 2004 Sep; 87(4):162-6. PubMed ID: 15334630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
    Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
    Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation.
    Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Abbolito MR; Mariotti S; Aloe S; Carone MD; Graziano F; Tedesco M; Martini F; Mancini R; Stigliano V; Roselli M; Guadagni F
    Anticancer Res; 2001; 21(2B):1263-70. PubMed ID: 11396197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer.
    Wang JY; Lu CY; Chu KS; Ma CJ; Wu DC; Tsai HL; Yu FJ; Hsieh JS
    Eur Surg Res; 2007; 39(4):245-50. PubMed ID: 17457032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen.
    Huber K; Kirchheimer JC; Sedlmayer A; Bell C; Ermler D; Binder BR
    Cancer Res; 1993 Apr; 53(8):1788-93. PubMed ID: 8467497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
    Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
    Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
    Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
    Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.